Compare WLDS & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLDS | EDSA |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | Israel | Canada |
| Employees | N/A | N/A |
| Industry | Computer Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9M | 12.3M |
| IPO Year | 2022 | N/A |
| Metric | WLDS | EDSA |
|---|---|---|
| Price | $1.06 | $1.35 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | ★ 371.1K | 43.8K |
| Earning Date | 03-09-2026 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $422,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.00 | $1.28 |
| 52 Week High | $11.40 | $4.49 |
| Indicator | WLDS | EDSA |
|---|---|---|
| Relative Strength Index (RSI) | 33.42 | 35.24 |
| Support Level | $1.08 | $1.41 |
| Resistance Level | $1.13 | $1.54 |
| Average True Range (ATR) | 0.09 | 0.06 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 12.07 | 4.35 |
Wearable Devices Ltd develops and sells human-machine interface solutions for the smart wearables industry. These digital devices include consumer electronics, smart watches, smartphones, AR glasses, VR headsets, televisions, PCs, laptop computers, drones, robots, etc. The company has completed the transition phase from research and development to commercialization of technology into B2B and B2C products. Its products include Mudra Inspire, a band for the Apple Watch that allows touchless operation and control of Apple ecosystem devices such as iPhone, Mac computer, Apple TV, and iPad, inter alia.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.